Kagocel

Kagocel is marketed as an antiviral for colds and flu, with claims that it boosts the body's own interferon. It hasn't shown convincing benefit for these infections, and there's no solid evidence base for this use. A cold or flu usually clears on its own within a few days, and supportive care helps most: fluids, rest, and a fever reducer if needed. For severe flu or a high risk of complications, ask your doctor about antivirals with proven effectiveness.

ICD-10: J00 · ICD-11: CA00

Kagocel is an antiviral marketed in Russia to prevent and treat colds and flu and to support immunity. Independent evidence has not shown convincing benefit for this use. For colds and flu, rest, fluids, and fever relief as needed help most, the annual flu shot gives real protection, and for severe flu a doctor may prescribe drugs with proven effect.

Kagocel is an antiviral promoted for treating and preventing influenza and other respiratory infections. Studies have not shown convincing benefit against flu, and there is no solid evidence base for this use. The substance itself is harmless in this role. What actually helps with influenza is vaccination before the season and, in the first days of illness, antivirals with proven effect (such as oseltamivir) chosen by a doctor; otherwise rest, fluids and symptom relief.

ICD-10: J10-J11 · ICD-11: 1E32

Evidence tier F. Kagocel for herpes simplex infection is not mentioned in international guidelines (CDC STI 2021, IUSTI 2017, IDSA). Evidence-based antiviral therapy for genital, orolabial and severe systemic herpes simplex consists of nucleoside analogues - aciclovir, valaciclovir and famciclovir - either episodically or as suppressive therapy in patients with frequent recurrences. Adding kagocel to nucleoside therapy has no demonstrated benefit and is not part of any international recommendation.

ICD-10: B00 · ICD-11: 1F00.Z